An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results allow for the further development of the program to Phase 1 Utrecht, the Netherlands, and Lyon, France, 8 June 2022 – Nosopharm, a biotechnology company specializ...